· On Dec. 8, the U.S. Food and Drug Administration (FDA) approved:
· Vonvendi, von Willebrand factor (Recombinant), for use in adults 18 years of age and older who have von Willebrand disease (VWD). Vonvendi is the first FDA-approved recombinant von Willebrand factor, and is approved for treatment and control of bleeding episodes in adults diagnosed with VWD. Read more.
· Kanuma (sebelipase alfa) as the first treatment for patients with lysosomal acid lipase (LAL) deficiency. Read more.
FDA approves new drugs
The views and opinions expressed here are those of the author and do not necessarily reflect the opinions or recommendations of the American Nurses Association, the Editorial Advisory Board members, or the Publisher, Editors and staff of American Nurse Journal. This has not been peer reviewed.
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.
NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
